Preferential Treatment in the ER?

Today’s New York Times has a well-written, informative, and potentially explosive article, “How NYU’s Emergency Room Favors the Rich.” Here’s a summary, but read the whole thing for the full scoop:

In New York University’s busy Manhattan emergency department, Room 20 is special.

Steps away from the hospital’s ambulance bay, the room is outfitted with equipment to perform critical procedures or isolate those with highly infectious diseases.

Doctors say Room 20 is usually reserved for two types of patients: Those whose lives are on the line. And those who are V.I.P.s.

NYU Langone denies putting V.I.P.s first, but 33 medical workers told The New York Times that they had seen such patients receive preferential treatment in Room 20, one of the largest private spaces in the department. One doctor was surprised to find an orthopedic specialist in the room awaiting a senior hospital executive’s mother with hip pain. Another described an older hospital trustee who was taken to Room 20 when he was short of breath after exercising.

The privileged treatment is part of a broader pattern, a Times investigation found. For years, NYU’s emergency room in Manhattan has secretly given priority to donors, trustees, politicians, celebrities, and their friends and family, according to 45 medical workers, internal hospital records and other confidential documents reviewed by The Times.

Continue reading

Fatal Vision: Boosters, Variants, and Equity

Getting a booster is no panacea, but not getting one may be a fatal mistake. That, at any rate, is the finding of a set of Israeli studies in the New England Journal of Medicine, one published in October, the other published just a few days ago. An excerpt from the abstract of the “Conclusions” section of the latter:

Across the age groups studied, rates of confirmed Covid-19 and severe illness were substantially lower among participants who received a booster dose of the BNT162b2 vaccine than among those who did not.

Read both articles all the way through for all of the relevant provisos and qualifications, but I think it’s fair to summarize both by saying that they jointly found that boosters reduced the incidence of both serious morbidity and mortality due to COVID-19, inclusive of all variants but Omicron (about which it’s too early to tell). Continue reading